Using MIDD to Bridge Indications & Optimise Dose Selection
9:00 am - Thursday 19th November 2026
- Leveraging clinical pharmacology and quantitative modelling to translate evidence across therapeutic areas when applying established mechanisms to new patient populations
- Building models that account for differences in disease biology, treatment goals, and benefit-risk expectations across oncology and autoimmune indications
- Using MIDD to support first-in-indication dose selection when clinical data are available in one disease area but limited in another
- Understanding how therapeutic windows, safety tolerability, and dosing regimens must evolve when moving from oncology to chronic disease populations